The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed
Open accessAbstract
There is an urgent global need for new strategies and drugs to control and treat multidrug-resistant bacterial infections. In 2017, the World Health Organization (WHO) released a list of 12 antibiotic-resistant priority pathogens and began to critically analyze the antibacterial clinical pipeline. This review analyzes “traditional” and “nontraditional” antibacterial agents and modulators in clinical development current on 30 June 2021 with activity against the WHO priority pathogens mycobacteria and Clostridioides difficile .
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tacconelli, E., Carrara, E., Savoldi, A., Harbarth, S., Mendelson, M., Monnet, D. L., Pulcini, C., Kahlmeter, G., Kluytmans, J., Carmeli, Y., et al. (2018) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30753-3 · Cited by 6,142
Self-citationDrugs for bad bugs: confronting the challenges of antibacterial discovery
Payne, D. J., Gwynn, M. N., Holmes, D. J., & Pompliano, D. L. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2201 · Cited by 2,512
An analysis of FDA-approved drugs for infectious disease: antibacterial agents
Kinch, M. S., Patridge, E., Plummer, M., & Hoyer, D. (2014) · Drug Discovery Today · doi:10.1016/j.drudis.2014.07.005 · Cited by 115 · cited 2×
“This significant discrepancy in revenue helps to explain why most of the large pharmaceutical companies have either stopped or reduced their antibacterial R&D programs (19).”
Background
Cited by
Metals to combat antimicrobial resistance
Frei, A., Verderosa, A. D., Elliott, A. G., Zuegg, J., & Blaskovich, M. A. T. (2023) · Nature Reviews Chemistry · doi:10.1038/s41570-023-00463-4 · Cited by 638
Multidrug-resistant Gram-negative bacterial infections
Macesic, N., Uhlemann, A.-C., & Peleg, A. Y. (2025) · The Lancet · doi:10.1016/s0140-6736(24)02081-6 · Cited by 315
Tackling the outer membrane: facilitating compound entry into Gram-negative bacterial pathogens
Saxena, D., Maitra, R., Bormon, R., Czekanska, M., Meiers, J., Titz, A., Verma, S., & Chopra, S. (2023) · npj Antimicrobials and Resistance · doi:10.1038/s44259-023-00016-1 · Cited by 217
Peukert, C., Gasser, V., Orth, T., Fritsch, S., Normant, V., Cunrath, O., Schalk, I. J., & Brönstrup, M. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01489 · Cited by 34
de Souza, A. Á., Lima, A. M., dede Oliveira BezerraSousa, D., Nogueira, F. C., do Sacramento Neto, J. C., Dias, L. P., Araújo, N. M. S., Nagano, C. S., Júnior, H. V. N., da Silva, C. R., et al. (2023) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-022-09979-5 · Cited by 8
Metadata
- Authors
- Butler, M. S., Gigante, V., Sati, H., Paulin, S., Al-Sulaiman, L., Rex, J. H., Fernandes, P., Arias, C. A., Paul, M., Thwaites, G. E., Czaplewski, L., Alm, R. A., Lienhardt, C., Spigelman, M., Silver, L. L., Ohmagari, N., Kozlov, R., Harbarth, S., & Beyer, P.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2022-03-15
- Volume
- 66
- Issue
- 3
- Pages
- e0199121-e0199121
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W4205388647
- Cited by
- 252
- References
- 3
- FWCI
- 14.95
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed. https://app.cochat.ai/papers/10.1128/aac.01991-21
- The paper
- Butler, M. S., Gigante, V., Sati, H., Paulin, S., Al-Sulaiman, L., Rex, J. H., Fernandes, P., Arias, C. A., Paul, M., Thwaites, G. E., Czaplewski, L., Alm, R. A., Lienhardt, C., Spigelman, M., Silver, L. L., Ohmagari, N., Kozlov, R., Harbarth, S., & Beyer, P. (2022). Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.01991-21
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.